drugset / Trial / NCT00855361
A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the pharmacokinetics, pharmacodynamics, and the safety of rabeprazole sodium for the treatment of gastroesophageal reflux disease (GERD) in newborns and pre-term infants.
Timeline
- Start
- 2009-07
- Primary completion
- 2011-12
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rabeprazole | Small molecule | 1 mg | Other |
| Subject | Rabeprazole | Small molecule | 2 mg | Other |
| Subject | Rabeprazole | Small molecule | 3 mg | Other |